In the study using a mouse NASH model, WAY-362450 administration for 4 weeks significantly attenuated the inflammation and fibrosis in liver and reduced the levels of serum ALT and AST [110]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.